Gaudium IVF
Gaudium IVF Q1 FY27: Capex ₹25 Cr
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance. The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
From Gaudium IVF's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance.
- Q1 revenue grew by 9%, influenced by typical seasonal slowdowns in IVF treatments during quarter 1 due to heat-related patient behavior and ongoing integration of new technology and hubs.
- Full-year growth target of 30% is supported by new hubs becoming operational, especially South Extension in New Delhi and upcoming locations.
- The flagship Janakpuri center continues to grow roughly at 30% year-on-year.
- Expansion includes opening 10 new hubs in FY27 and a women’s hospital in Lucknow (expected to commercialize in FY28-29).
2 more points from Gaudium IVF's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gaudium IVF said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current FY27 Capex: ₹25 crores planned for 10 new IVF hubs, averaging ₹2.5 crores per hub (₹1 crore construction + ₹1.5 crores lab machinery). Funded mainly through IPO proceeds and internal accruals.
- Gaudium Women Hospital, Lucknow: Board approved up to ₹15 crores for project cost, to be incurred progressively over setup and commissioning in FY28-FY29. Funded mainly through internal accruals, not IPO proceeds.
- Capex Strategy: Focus on a debt-light, capital-efficient, asset-light hub-and-spoke rollout.
2 more points from Gaudium IVF's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gaudium IVF said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Gaudium IVF's call on order book
Pro opens every point from 15K+ earnings calls
Gaudium IVF — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹30 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gaudium IVF and Women Health Ltd's management said in earlier quarters
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
- Krsnaa Diagnostics Ltd (Q1 FY27)
. Key concall takeaways from Krsnaa Diagnost.'s Q1 FY27 earnings call — and how it ranks against sector peers.
- Artemis Medicare Services Ltd (Q1 FY27)
Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years. Key concall takeaways from Artemis Medicare Services Ltd's Q1 FY27 earnings…
Arthneeti Pro · Annual
Gaudium IVF and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gaudium IVF Q1 FY27 results?
The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance. The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
What is Gaudium IVF share price analysis?
Gaudium IVF currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 36.5 with a market cap of ₹846 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gaudium IVF planning capital expenditure?
Current FY27 Capex: ₹25 crores planned for 10 new IVF hubs, averaging ₹2.5 crores per hub (₹1 crore construction + ₹1.5 crores lab machinery).
Keep Gaudium IVF on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.